Intellia Therapeutics Announces Closing of Initial Public Offering

Intellia Therapeutics - Revolutionize the course of medicine

Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based ...

Intellia Therapeutics Announces Second Quarter 2022 Financial ...

Intellia announced today plans to discontinue its first-in-human study of NTLA-5001, an investigational autologous TCR-T cell therapy, and is ...

Intellia Therapeutics Announces Third Quarter 2023 Financial ...

09, 2023 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing ...

Intellia Therapeutics Announces First Quarter 2023 Financial ...

(NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing potentially curative therapies leveraging CRISPR-based ...

Intellia Therapeutics Reports Inducement Grants under Nasdaq ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...

D - Intellia Therapeutics - investor relations

This is the initial public offering of shares of our common stock. Prior to this offering, there has been no public market for our common stock. We are selling ...

Intellia Therapeutics Announces Third Quarter 2021 Financial ...

(NASDAQ:NTLA), a leading clinical-stage genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in ...

united states securities and exchange commission

... Company's initial public offering (“IPO”) of its Common Stock. The aggregate ... Intellia Therapeutics Announces Closing of. Initial Public Offering.

SEC Filing - Intellia Therapeutics - investor relations

Our common stock is listed on The Nasdaq Global Market under the symbol “NTLA”. The last sale price as reported on The Nasdaq Global Market on November 27, 2020 ...

Intellia Therapeutics Announces Positive Long-Term Data from ...

CAMBRIDGE, Mass. , June 02, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage genome editing company ...

INTELLIA THERAPEUTICS, INC.

In addition, the Company issued a total of 3,055,554 shares of common stock in two separate, concurrent private placements upon the closing of the IPO. The ...

SEC Filing - Intellia Therapeutics - investor relations

Our common stock is listed on The Nasdaq Global Market under the symbol “NTLA”. The last sale price as reported on The Nasdaq Global Market on October 31, 2017 ...

D - Intellia Therapeutics - investor relations

This is the initial public offering of shares of our common stock. Prior to ... The closing of this offering is not conditioned upon the closing of such ...

About - Intellia Therapeutics

Learn more about Intellia, a clinical-stage genome editing company, developing novel, potentially curative therapeutics using CRISPR.

intellia therapeutics, inc.

This is the initial public offering of shares of our common stock. Prior to ... The closing of this offering is not conditioned upon the closing of such ...

SEC Filing - Intellia Therapeutics - investor relations

... stock into common stock upon the closing of an initial public offering. For purposes of calculating pro forma basic and diluted loss per share, all shares ...

Intellia Therapeutics Announces Fourth Quarter and Full Year 2017 ...

CAMBRIDGE, Mass. , March 14, 2018 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on ...

INTELLIA THERAPEUTICS, INC.

A copy of the press release announcing the closing of the IPO is attached hereto as Exhibit 99.1 and is incorporated herein by reference. Item ...

SEC Filing - Intellia Therapeutics - investor relations

On May 11, 2016, the Company completed an initial public offering (“IPO”) of its common stock, which resulted in the sale of 6,900,000 shares, including all ...

INTELLIA THERAPEUTICS, INC.

... therapies may damage public perception of the safety of any product ... stock into common stock upon the closing of an initial public offering.